People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

18 Oct 2019
Change (% chg)

$-0.02 (-0.66%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bhadauria, Pradeep 

Mr. Pradeep Bhadauria is Chief Scientific Officer of the Company. Pradeep oversees Global Research & Development, Clinical Affairs and Regulatory Affairs and is responsible for driving the growth of our generics and specialty pipeline. He has more than 20 years of experience leading the development capabilities for several leading generic and specialty pharmaceutical companies. Throughout his career, his leadership has resulted in the development and filing of more than 200 products, including numerous first-to-file and first-to-market opportunities. Pradeep has deep expertise across nearly all dosage forms and demonstrated strength in helping companies diversify their pipelines and portfolios through complex generics, 505(B) 2s, investigational new drugs and new drug applications. Prior to joining Amneal, he served as Executive Vice President, Global R&D for Apotex, Inc., responsible for leading the company’s entire global R&D activities. He also managed a large generic R&D portfolio across many dosage forms for various global markets. Prior to joining Apotex, he served as Vice President – Generic R&D for Allergan/Actavis. Pradeep holds a Master of Pharmacy (M.Pharm) from the Birla Institute of Technology in India and a Bachelor of Pharmacy from SGSITS, Devi Ahilya University in India. He also holds several patents and has published research in various publications.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Paul Bisaro


Chintu Patel


Chirag Patel


Robert Stewart


Kanwal Pandita


Todd Branning

As Of  31 Dec 2018